ELAN Q2 2023 Earnings — Elanco Animal Health Incorporated Revenue & Financial Results | Market Cap Arena

ELANElanco Animal Health Incorporated

$12B

Q2 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$1.1B-10.0% YoY

Gross Profit

$487M46.1% margin

Operating Income

$53M5.0% margin

Net Income

-$97M-9.2% margin

EPS (Diluted)

$-0.20

QoQ Revenue Growth

-15.9%

Cash Flow

Operating Cash Flow

$61M

Free Cash Flow

$19M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$15.8B

Total Liabilities

$8.4B

Stockholders' Equity

$7.4B

Cash & Equivalents

$367M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.1B	$1.2B	-10.0%
Gross Profit	$487M	$558M	-12.7%
Operating Income	$53M	$133M	-60.2%
Net Income	-$97M	-$10M	-870.0%

Revenue Segments

Farm Animal

$527M34%

Pet Health

$518M34%

Cattle

$210M14%

Poultry

$178M12%

Swine

$89M6%

Contract Manufacturing

$12M1%

Geographic Segments

Non-US

$557M53%

UNITED STATES

$500M47%